IP Library › Granted Patent US 11,401,316
Granted Patent B2
US 11,401,316 · App. 15/768,740 · Granted Aug 2, 2022

High avidity HPV T-cell receptors

Inventors: Thomas Blankenstein (Berlin, DE); Gerald Willimsky (Berlin, DE)
Assignee: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT
C07K14/7051A61K39/12A61P31/20C07K14/005C07K16/08C07K16/084C12N5/0636A61K48/00A61K2039/5156A61K2039/5158A61K2039/585C07K2317/565C07K2318/00C12N2510/00C12N2710/20034
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,401,316
App. No.
15/768,740
Granted
Aug 2, 2022
Kind
B2
Abstract

The present invention pertains to novel high avidity antigen recognizing constructs against Human Papilloma Virus antigens. The invention provides novel T cell receptor (TCR) based molecules which are selective and specific for HPV 16/18 proteins E5, E6 and E7. The TCR of the invention, and HPV antigen-binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of HPV infection, as well as for the diagnosis, treatment and prevention of HPV infection mediated secondary diseases as HPV infection caused cancers, such as cervical, nasopharyngeal or head and neck cancer. Further provided are nucleic acids encoding the proteins of the invention, and recombinant cells expressing the same.

Claims (21)

1. An antigen recognizing construct comprising a T cell receptor (TCR), or an antigen binding fragment thereof, wherein the TCR or the antigen binding fragment thereof is composed of a TCR α chain sequence and a TCR β chain sequence, wherein

(i) the TCR α chain sequence comprises an α chain complementary determining region 3 (CDR3), wherein an amino acid sequence of the α chain CDR3 comprises only one sequence selected from the group consisting of SEQ ID Nos: 9, 10, 12, 14, 16, 18, 21, 23, 25, and 27, and

(ii) the TCR β chain sequence comprises a β chain CDR3; wherein an amino acid sequence of the β chain CDR3 comprises only one sequence selected from the group consisting of SEQ ID Nos: 11, 13, 15, 17, 19, 20, 22, 24, 26, and 28.

2. The antigen recognizing construct according to claim 1 , wherein said TCR comprises a CDR1 and a CDR2 having sequences as set forth in SEQ ID NOs: 29 and 31; or 30 and 31; or 32 and 33; or 34 and 35; or 36 and 37; or 38 and 39; or 38 and 40; or 41 and 42; or 43 and 44; or 45 and 46; or 47 and 48.

3. The antigen recognizing construct according to claim 1 , wherein said TCR comprises variable sequences as set forth in SEQ ID NOs: 29 and 31; or 30 and 31; or 32 and 33; or 34 and 35; or 36 and 37; or 38 and 39; or 38 and 40; or 41 and 42; or 43 and 44; or 45 and 46; or 47 and 48.

4. A nucleic acid encoding for an antigen recognizing construct according to claim 1 .

5. A vector comprising a nucleic acid according to claim 4 .

6. An isolated host cell comprising an antigen recognizing construct according to claim 1 .

7. The host cell according to claim 6 , comprising a lymphocyte.

8. An isolated host cell comprising a nucleic acid according to claim 4 .

9. An isolated host cell comprising a vector according to claim 5 .

10. The antigen recognizing construct according to claim 1 , wherein the amino acid sequence of the α chain CDR3 consists of SEQ ID No. 9 or 10, and wherein the amino acid sequence of the β chain CDR consists of SEQ ID No. 11.

11. The antigen recognizing construct according to claim 1 , wherein the amino acid sequence of the α chain CDR3 consists of SEQ ID No. 12, and wherein the amino acid sequence of the β chain CDR consists of SEQ ID No. 13.

12. The antigen recognizing construct according to claim 1 , wherein the amino acid sequence of the α chain CDR3 consists of SEQ ID No. 14, and wherein the amino acid sequence of the β chain CDR consists of SEQ ID No. 15.

13. The antigen recognizing construct according to claim 1 , wherein the amino acid sequence of the α chain CDR3 consists of SEQ ID No. 16, and wherein the amino acid sequence of the β chain CDR consists of SEQ ID No. 17.

14. The antigen recognizing construct according to claim 1 , wherein the amino acid sequence of the α chain CDR3 consists of SEQ ID No. 18, and wherein the amino acid sequence of the β chain CDR consists of SEQ ID No. 20.

15. The antigen recognizing construct according to claim 1 , wherein the amino acid sequence of the α chain CDR3 consists of SEQ ID No. 21, and wherein the amino acid sequence of the β chain CDR consists of SEQ ID No. 22.

16. The antigen recognizing construct according to claim 1 , wherein the amino acid sequence of the α chain CDR3 consists of SEQ ID No. 23, and wherein the amino acid sequence of the β chain CDR consists of SEQ ID No. 24.

17. The antigen recognizing construct according to claim 1 , wherein the amino acid sequence of the α chain CDR3 consists of SEQ ID No. 25, and wherein the amino acid sequence of the β chain CDR consists of SEQ ID No. 26.

18. The antigen recognizing construct according to claim 1 , wherein the amino acid sequence of the α chain CDR3 consists of SEQ ID No. 27, and wherein the amino acid sequence of the β chain CDR consists of SEQ ID No. 28.

19. The antigen recognizing construct according to claim 1 , wherein the amino acid sequence of the α chain CDR3 consists of SEQ ID No, 19, and wherein the amino acid sequence of the β chain CDR consists of SEQ ID No. 20.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 16, 2018
From: BLANKENSTEIN, THOMAS; WILLIMSKY, GERALD, DR.
To: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT
Reel/Frame 045554/0431 →
Priority Claims (1)
EP 15190230 · Oct 16, 2015 · regional
Continuity (1)
Related Publication 20190062398A1 · Feb 28, 2019